X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (135) 135
oncology (130) 130
index medicus (120) 120
female (83) 83
male (75) 75
lung neoplasms - drug therapy (73) 73
middle aged (68) 68
lung neoplasms - pathology (64) 64
aged (63) 63
carcinoma, non-small-cell lung - drug therapy (58) 58
chemotherapy (54) 54
adult (47) 47
respiratory system (46) 46
lung cancer (45) 45
lung cancer, non-small cell (45) 45
mutation (44) 44
cancer (41) 41
carcinoma, non-small-cell lung - pathology (38) 38
nsclc (35) 35
gefitinib (33) 33
lung neoplasms - genetics (33) 33
lung neoplasms (32) 32
hematology, oncology and palliative medicine (31) 31
non-small cell lung cancer (30) 30
treatment outcome (30) 30
antineoplastic agents - therapeutic use (29) 29
egfr (28) 28
aged, 80 and over (27) 27
pulmonary/respiratory (27) 27
carcinoma, non-small-cell lung - genetics (26) 26
care and treatment (26) 26
neoplasm staging (26) 26
prognosis (26) 26
adenocarcinoma (25) 25
protein kinase inhibitors - therapeutic use (25) 25
research (25) 25
cancer research (24) 24
erlotinib (24) 24
respiratory tract diseases (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
cell lung-cancer (23) 23
therapy (23) 23
analysis (22) 22
receptor, epidermal growth factor - genetics (22) 22
survival (22) 22
immunohistochemistry (21) 21
open-label (20) 20
pulmonary and respiratory medicine (20) 20
acquired-resistance (18) 18
lung neoplasms - mortality (18) 18
patients (18) 18
carcinoma, non-small-cell lung (17) 17
drug resistance, neoplasm (17) 17
genetic aspects (17) 17
crizotinib (16) 16
epidermal growth factor (16) 16
expression (16) 16
medicine (16) 16
diagnosis (15) 15
health aspects (15) 15
metastasis (15) 15
tumors (15) 15
antineoplastic agents - pharmacology (14) 14
carboplatin (14) 14
lung neoplasms - metabolism (14) 14
mutations (14) 14
receptor, epidermal growth factor - antagonists & inhibitors (14) 14
tomography, x-ray computed (14) 14
cancer therapies (13) 13
carcinoma, non-small-cell lung - mortality (13) 13
immunotherapy (13) 13
resistance (13) 13
retrospective studies (13) 13
survival analysis (13) 13
trial (13) 13
cisplatin (12) 12
development and progression (12) 12
neoplasms (12) 12
pharmacology & pharmacy (12) 12
phase-ii (12) 12
protein kinase inhibitors - pharmacology (12) 12
adenocarcinoma - pathology (11) 11
antineoplastic agents (11) 11
cell line, tumor (11) 11
docetaxel (11) 11
egfr mutation (11) 11
erbb receptors - genetics (11) 11
kinases (11) 11
receptor, epidermal growth factor (11) 11
tyrosine kinase inhibitors (11) 11
antineoplastic agents - adverse effects (10) 10
bevacizumab (10) 10
disease progression (10) 10
disease-free survival (10) 10
drug resistance, neoplasm - genetics (10) 10
lung cancer, small cell (10) 10
neoplasms. tumors. oncology. including cancer and carcinogens (10) 10
quinazolines - pharmacology (10) 10
quinazolines - therapeutic use (10) 10
review (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2015, Volume 4, Issue 5, pp. 584 - 597
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1652 - 1664
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2018, Volume 119, Issue 10, pp. 1252 - 1258
BACKGROUND: Circulating cell-free DNA (cfDNA) may help understand the molecular response to pharmacologic treatment and provide information on dynamics of... 
HETEROGENEITY | AMPLIFICATION | PLASMA | NSCLC | ONCOLOGY | RESISTANCE | MECHANISMS | PATIENT | EMERGENCE | AZD9291 | Heterogeneity | Epidermal growth factor receptors | Gene frequency | Correlation analysis | Non-small cell lung carcinoma | Pharmacology | Mutation | Patients | Deoxyribonucleic acid--DNA
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2019
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 05/2015, Volume 10, Issue 5, p. e35
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2015, Volume 10, Issue 11, p. e0141795
Background BCRP/ABCG2 emerged as an important multidrug resistance protein, because it confers resistance to several classes of cancer chemotherapeutic agents... 
TYROSINE KINASE INHIBITORS | LUNG-CANCER | TRANSPORTER | MEDIATED DRUG-RESISTANCE | MODULATORS | SUBSTRATE | MULTIDISCIPLINARY SCIENCES | MECHANISMS | MULTIDRUG-RESISTANCE | BINDING | CANCER RESISTANCE PROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Receptor, Epidermal Growth Factor - genetics | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Neoplasm Proteins - antagonists & inhibitors | Chromatography, High Pressure Liquid | Neoplasm Proteins - metabolism | Tandem Mass Spectrometry | ATP-Binding Cassette Transporters - genetics | Biological Transport | Protein Kinase Inhibitors - analysis | RNA Interference | HEK293 Cells | ATP-Binding Cassette Transporters - metabolism | Indoles - pharmacology | Neoplasm Proteins - genetics | Quinazolines - analysis | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - metabolism | Gene Expression Regulation - drug effects | Quinazolines - toxicity | Cell Line, Tumor | Protein Kinase Inhibitors - toxicity | ATP-Binding Cassette Transporters - antagonists & inhibitors | RNA, Small Interfering - metabolism | Care and treatment | Chemotherapy | Patient outcomes | Development and progression | Genetic aspects | Research | Drug resistance | Lung cancer, Non-small cell | Health aspects | Cancer | Cell culture | Biotechnology | Leukemia | Genes | Lung cancer | Kinases | Cancer therapies | Accumulation | Proteins | Epidermal growth factor | Metabolites | Rodents | ABC transporters | Gefitinib | Protein-tyrosine kinase | Tyrosine | Efflux | Nutrient transport | Epidermal growth factor receptors | Multidrug resistance | Non-small cell lung carcinoma | Substrate inhibition | Breast cancer | Metabolism | Substrates | Medicine | Inhibitors | Cell lines | Mutation | Intracellular | Transporter | Binding sites | Tumors | Glutamine
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2016, Volume 5, Issue 6, pp. 695 - 708
Journal Article
Current Drug Targets, ISSN 1389-4501, 2016, Volume 17, Issue 15, pp. 1755 - 1760
Background: Sporadic data are available about pazopanib use in patients with metastatic renal cell carcinoma (mRCC) undergoing dialysis and no systematic... 
Dialysis | Dose titration | TKI | Hemodialysis | Renal cell carcinoma | Pazopanib | EFFICACY | pazopanib | CANCER | TRIAL | dose titration | renal cell carcinoma | PHARMACOKINETICS | hemodialysis | DOUBLE-BLIND | SUNITINIB | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | DRUG-METABOLISM | GENETIC-MARKERS
Journal Article
Handbook of experimental pharmacology, ISSN 0171-2004, 2018, Volume 249, pp. 63 - 89
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2490 - 2498
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 799 - 811
Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of... 
Clinical trials | Mesothelioma | Analysis
Journal Article